Olprinone

Drug Profile

Olprinone

Alternative Names: Coretec; E 1020; Loprinone

Latest Information Update: 04 Aug 2005

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Class Bronchodilators; Cardiotonics; Imidazoles; Pyridones; Small molecules
  • Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Heart failure
  • Discontinued Acute asthma; Asthma; Reperfusion injury

Most Recent Events

  • 04 Aug 2005 Discontinued - Clinical-Phase-Unknown for Acute asthma in Japan (IV-infusion)
  • 04 Aug 2005 Discontinued - Clinical-Phase-Unknown for Asthma in Japan (Inhalation)
  • 04 Aug 2005 Discontinued - Clinical-Phase-Unknown for Reperfusion injury in Japan (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top